Combination effect of AMD3100 and dexamethasone on the mobilization of hematopoietic stem cells

doi:10.3969/j.issn.2095-4344.2016.36.005

Abstract

Abstract:

BACKGROUND: The number of hematopoietic stem cells in the peripheral blood is very low at normal physiological state. So it is critical to mobilize hematopoietic stem cells from donor’s bone marrow into the peripheral blood.
OBJECTIVE: To study the combination effect of AMD3100 and dexamethasone on the mobilization of hematopoietic stem cells in mice, thereby laying the foundation for clinical application.
METHODS: C57BL/6 mice were injected with AMD3100 and dexamethasone alone or in combination. Then, hematopoietic stem cells in the peripheral blood and bone marrow were collected. CD34⁺ cell concentration in the peripheral blood and bone marrow was determined by flow cytometer and the content of leucocytes in the peripheral blood was counted by a normal method. The CFU-Mix colony formation ability of hematopoietic stem cells was identified by cell colony forming assay.
RESULTS AND CONCLUSION: The concentration of CD34⁺ cells in the peripheral blood and bone marrow, the content of leukocytes in the peripheral blood and the CFU-Mix colony formation ability of hematopoietic stem cells were all improved by both AMD3100 and dexamethasone and especially their combined use. This indicates that both AMD3100 and dexamethasone could mobilize hematopoietic stem cells to migrate from the bone marrow to the peripheral blood, and when used in combination, the mobilization effect is better than that of single drug.

中国组织工程研究杂志出版内容重点：干细胞；骨髓干细胞；造血干细胞；脂肪干细胞；肿瘤干细胞；胚胎干细胞；脐带脐血干细胞；干细胞诱导；干细胞分化；组织工程

Key words: Hematopoietic Stem Cell Transplantation, Dexamethasone, Hematopoietic Stem Cell Mobilization, Tissue Engineering

CLC Number:

R394.2

Yan Bei-zhan, Ma Hui-min, Kong Cun-quan, Liang Yu, Zhu Wei-yan, Jiang Shu-ting . Combination effect of AMD3100 and dexamethasone on the mobilization of hematopoietic stem cells[J]. Chinese Journal of Tissue Engineering Research, 2016, 20(36): 5351-5357.

Figures/Tables 1

References

[1] 王东红. 造血干细胞及其潜能[J]. 卫生职业教育, 2004, 22(6): 121-123.
[2] Passweg JR, Halter J, Bucher C, et al. Hematopoietic stem cell transplantation: a review and recommendations for follow-up care for the general practitioner. Swiss Med Wkly. 2012;142:w13696.
[3] Nervi B, Link DC, DiPersio JF. Cytokines and hematopoietic stem cell mobilization. J Cell Biochem. 2006;99(3):690-705.
[4] 饶彪锋,潘秀英,陆晔,等. AMD3100动员造血干/祖细胞的实验研究[J].江苏医药, 2012,38(5):516-518.
[5] Hopman RK, DiPersio JF. Advances in stem cell mobilization. Blood Rev. 2014;28(1):31-40.
[6] Guyon A. CXCL12 chemokine and its receptors as major players in the interactions between immune and nervous systems. Front Cell Neurosci. 2014; 8:65.
[7] Yang P, Wang G, Huo H, et al. SDF-1/CXCR4 signaling up-regulates survivin to regulate human sacral chondrosarcoma cell cycle and epithelial-mesenchymal transition via ERK and PI3K/AKT pathway. Med Oncol. 2015;32(1):377.
[8] Lin CH, Shih CH, Tseng CC, et al. CXCL12 induces connective tissue growth factor expression in human lung fibroblasts through the Rac1/ERK, JNK, and AP-1 pathways. PLoS One. 2014;9(8):e104746.
[9] Yu T, Liu K, Wu Y, et al. MicroRNA-9 inhibits the proliferation of oral squamous cell carcinoma cells by suppressing expression of CXCR4 via the Wnt/β-catenin signaling pathway. Oncogene. 2014; 33(42):5017-5027.
[10] Zhao S, Wang J, Qin C. Blockade of CXCL12/CXCR4 signaling inhibits intrahepatic cholangiocarcinoma progression and metastasis via inactivation of canonical Wnt pathway. J Exp Clin Cancer Res. 2014; 33:103.
[11] Kucia M, Reca R, Miekus K, et al. Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem Cells. 2005;23(7):879-894.
[12] Sugiyama T, Kohara H, Noda M, et al. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches.Immunity. 2006;25(6):977-988.
[13] Ratajczak MZ, Kim CH, Abdel-Latif A, et al. A novel perspective on stem cell homing and mobilization: review on bioactive lipids as potent chemoattractants and cationic peptides as underappreciated modulators of responsiveness to SDF-1 gradients. Leukemia. 2012;26(1):63-72.
[14] Wuchter P, Leinweber C, Saffrich R, et al. Plerixafor induces the rapid and transient release of stromal cell-derived factor-1 alpha from human mesenchymal stromal cells and influences the migration behavior of human hematopoietic progenitor cells. Cell Tissue Res. 2014;355(2):315-326.
[15] Li J, Hamilton E, Vaughn L, et al. Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics. Transfusion. 2011; 51(10):2175-2182.
[16] Tekgündüz E, Altunta? F, S?vg?n S, et al. Plerixafor use in patients with previous mobilization failure: A multicenter experience. Transfus Apher Sci. 2012; 47(1): 77-80.
[17] Emir S, Demir HA, Aksu T, et al. Use of plerixafor for peripheral blood stem cell mobilization failure in children. Transfus Apher Sci. 2014;50(2):214-218.
[18] Pandey MK, Rastogi S, Kale VP, et al. Targeting CXCL12/CXCR4 Axis in Multiple Myeloma. J Hematol Thrombo Dis 2014; 2:159.
[19] Fricker SP. Physiology and pharmacology of plerixafor. Transfus Med Hemother. 2013;40(4):237-245.
[20] 王良绪,禹涛.自体外周血干细胞的动员和采集及其移植效果的研究[J].中华内科杂志,1995,34(10):659-662.
[21] Maiolino A, Hungria VT, Garnica M, et al. Thalidomide plus dexamethasone as a maintenance therapy after autologous hematopoietic stem cell transplantation improves progression-free survival in multiple myeloma. Am J Hematol. 2012;87(10):948-952.
[22] Liles WC, Huang JE, Llewellyn C, et al. A comparative trial of granulocyte-colony-stimulating factor and dexamethasone, separately and in combination, for the mobilization of neutrophils in the peripheral blood of normal volunteers. Transfusion. 1997;37(2):182-187.
[23] Liles WC, Rodger E, Dale DC. Combined administration of G-CSF and dexamethasone for the mobilization of granulocytes in normal donors: optimization of dosing. Transfusion. 2000;40(6): 642-644.
[24] Heuft HG, Goudeva L, Sel S, et al. Equivalent mobilization and collection of granulocytes for transfusion after administration of glycosylated G-CSF (3 microg/kg) plus dexamethasone versus glycosylated G-CSF (12 microg/kg) alone. Transfusion. 2002;42(7):928-934.
[25] Kikukawa Y, Yuki H, Hirata S, et al. Combined use of bortezomib, cyclophosphamide, and dexamethasone induces favorable hematological and organ responses in Japanese patients with amyloid light-chain amyloidosis: a single-institution retrospective study. Int J Hematol. 2015;101(2):133-139.
[26] Cavo M, Pantani L, Petrucci MT, et al. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood. 2012;120(1):9-19.
[27] Kessler K, Goudeva L, Heuft HG. Lenograstim with or without dexamethasone for neutrophil mobilization in healthy donors: short-term kinetics of white blood cells and effects of granulocyte apheresis. J Clin Apher. 2011;26(6):338-346.
[28] Kucia M, Jankowski K, Reca R, et al. CXCR4-SDF-1 signalling, locomotion, chemotaxis and adhesion. J Mol Histol. 2004;35(3):233-245.
[29] Ma Q, Jones D, Borghesani PR, et al. Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. Proc Natl Acad Sci U S A. 1998; 95(16):9448-9453.
[30] Slater S.Plerixafor. J Adv Pract Oncol. 2012;3(1): 49-54.
[31] Dar A, Schajnovitz A, Lapid K, et al. Rapid mobilization of hematopoietic progenitors by AMD3100 and catecholamines is mediated by CXCR4-dependent SDF-1 release from bone marrow stromal cells. Leukemia. 2011;25(8):1286-1296.
[32] Cashen AF. Plerixafor hydrochloride: a novel agent for the mobilization of peripheral blood stem cells. Drugs Today (Barc). 2009;45(7):497-505.
[33] Krause DS, Ito T, Fackler MJ, et al. Characterization of murine CD34, a marker for hematopoietic progenitor and stem cells. Blood. 1994;84(3):691-701.
[34] Lataillade JJ, Clay D, Dupuy C, et al. Chemokine SDF-1 enhances circulating CD34(+) cell proliferation in synergy with cytokines: possible role in progenitor survival. Blood. 2000;95(3):756-768.
[35] Villa CH, Shore T, Van Besien K, et al. Addition of plerixafor to mobilization regimens in autologous peripheral blood stem cell transplants does not affect the correlation of preharvest hematopoietic precursor cell enumeration with first-harvest CD34+ stem cell yield. Biol Blood Marrow Transplant. 2012;18(12): 1867-1875.
[36] Maziarz RT, Nademanee AP, Micallef IN, et al. Plerixafor plus granulocyte colony-stimulating factor improves the mobilization of hematopoietic stem cells in patients with non-Hodgkin lymphoma and low circulating peripheral blood CD34+ cells. Biol Blood Marrow Transplant. 2013;19(4):670-675.
[37] 李艳萍,彭世义.穴位注射地塞米松治疗Ⅳ度白细胞减少疗效观察[J].现代医药卫生, 2014, 30(18):2796-2797.
[38] 胡晶,吴宏.当归多糖对小鼠外周血造血干细胞动员作用的研究[J].中草药, 2007, 37(12): 1835-1838.
[39] Papoff P, Christensen RD, Harcum J, et al. In vitro effect of dexamethasone phosphate on hematopoietic progenitor cells in preterm infants. Arch Dis Child Fetal Neonatal Ed. 1998;78(1):F67-69.
[40] Golde DW, Bersch N, Quan SG, et al. Inhibition of murine granulopoiesis in vitro by dexamethasone. Am J Hematol. 1976;1(4):369-373.
[41] Winkler IG, Pettit AR, Raggatt LJ, et al. Hematopoietic stem cell mobilizing agents G-CSF, cyclophosphamide or AMD3100 have distinct mechanisms of action on bone marrow HSC niches and bone formation. Leukemia. 2012;26(7):1594-1601.
[42] Caulfield J, Fernandez M, Snetkov V, et al. CXCR4 expression on monocytes is up-regulated by dexamethasone and is modulated by autologous CD3+ T cells. Immunology. 2002;105(2):155-162.
[43] Ghosh MC, Baatar D, Collins G, et al. Dexamethasone augments CXCR4-mediated signaling in resting human T cells via the activation of the Src kinase Lck. Blood. 2009;113(3):575-584.